SCHEDULE 13G/A 0001104659-24-079033 0001940272 XXXXXXXX LIVE 4 Common Stock, par value $0.0001 per share 12/31/2025 0001444192 Grace Therapeutics, Inc. 00439U104 103 Carnegie Center Suite 300 Princeton NJ 08540 Rule 13d-1(b) ADAR1 Capital Management, LLC b TX 0.00 1646173.00 0.00 1646173.00 1646173.00 N 9.9 IA OO Includes (i) 618,397 shares of common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP, (ii) 23,591 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 1,004,185 shares of Common Stock underlying prefunded and milestone warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC as of December 31, 2025. Excludes 1,671,362 shares of Common Stock underlying prefunded and milestone warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC, the exchange and exercise of which are subject to 9.99% beneficial ownership limitations. As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. Based on 15,474,026 shares of Common Stock of Grace Therapeutics, Inc. (the "Issuer") outstanding as of December 31, 2025, reported in the Issuer's Form 10-Q for the quarterly period ended December 31, 2025, filed with the Securities and Exchange Commission on February 12, 2026. ADAR1 Capital Management GP, LLC b TX 0.00 1648791.00 0.00 1648791.00 1648791.00 N 9.9 OO Includes (i) 618,397 shares of common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP and (iii) 1,030,394 shares of Common Stock underlying prefunded and milestone warrants held by ADAR1 Partners, LP as of December 31, 2025. Excludes 1,179,363 shares of Common Stock underlying prefunded and milestone warrants held by ADAR1 Partners, the exchange and exercise of which are subject to the 9.99% beneficial ownership limitations. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. Based on 15,474,026 shares of Common Stock of Grace Therapeutics, Inc. (the "Issuer") outstanding as of December 31, 2025, reported in the Issuer's Form 10-Q for the quarterly period ended December 31, 2025, filed with the Securities and Exchange Commission on February 12, 2026. Daniel Schneeberger b V8 0.00 1646173.00 0.00 1646173.00 1646173.00 N 9.9 HC IN Includes (i) 618,397 shares of common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP, (ii) 23,591 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 1,004,185 shares of Common Stock underlying prefunded and milestone warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC as of December 31, 2025. Excludes 1,671,362 shares of Common Stock underlying prefunded and milestone warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC, the exchange and exercise of which are subject to 9.99% beneficial ownership limitations. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. Based on 15,474,026 shares of Common Stock of Grace Therapeutics, Inc. (the "Issuer") outstanding as of December 31, 2025, reported in the Issuer's Form 10-Q for the quarterly period ended December 31, 2025, filed with the Securities and Exchange Commission on February 12, 2026. Grace Therapeutics, Inc. 103 Carnegie Center, Suite 300, Princeton, NJ 08540 This Schedule is being filed on behalf of each of the following persons (each, a "Reporting Person" and collectively, the "Reporting Persons"): (i) ADAR1 Capital Management, LLC ("ADAR1 Capital Management"); (ii) ADAR1 Capital Management GP, LLC ("ADAR1 General Partner"); and (iii) Daniel Schneeberger ("Mr. Schneeberger"). The address of the principal business office of each of the Reporting Persons is 3503 Wild Cherry Drive, Building 9, Austin, Texas 78738. (i) ADAR1 Capital Management is a Texas limited liability company; (ii) ADAR1 General Partner is a Texas limited liability company; and (iii) Mr. Schneeberger is a citizen of Switzerland. N IA HC The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. Y Y N Mr. Schneeberger is filing this Schedule 13G as a control person in respect of shares beneficially owned by ADAR1 Capital Management, an investment adviser as described in SS 240.13d-1(b)(1)(ii)(E). Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. ADAR1 Capital Management, LLC /s/ Daniel Schneeberger 02/17/2026 ADAR1 Capital Management GP, LLC /s/ Daniel Schneeberger 02/17/2026 Daniel Schneeberger /s/ Daniel Schneeberger 02/17/2026